CBT-I in Older African American Adults
Sleep problems, like insomnia, are common in older African Americans. About 25% of older adults in the US have at least 2 symptoms of insomnia, such as having trouble falling asleep, staying asleep, or getting good sleep for a month or more. Cognitive Behavioral Therapy for Insomnia (CBT-I) is a recommended non-pharmac
| Condition(s) | Older Adults (65 Years and Older) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Sleep problems, like insomnia, are common in older African Americans. About 25% of older adults in the US have at least 2 symptoms of insomnia, such as having trouble falling asleep, staying asleep, or getting good sleep for a month or more. Cognitive Behavioral Therapy for Insomnia (CBT-I) is a recommended non-pharmacological treatment for insomnia. Unlike medicines that might only help for a short time or have many side effects, CBT-I deals with the root causes of insomnia. It helps people change how they think and act about sleep, leading to better habits and attitudes. This can make sleep better for a long time, even after the treatment is over. While CBT-I is commonly used among adults with insomnia, its benefits among older adults and specifically older African American adults are no |
| Who can participate | Inclusion Criteria: * Reading level 6th grade or better and can speak and understand English well. * Self-identify as African American or Black. * Ages 60 and over. * Score of \>2 in PSQI sleep duration, sleep disturbance, or overall sleep quality calculated components. * Participating in the "Pathways to Healthy Aging in African Americans" study. * Has established chronic insomnia issues for at least three months. * Subjects must be willing to participate in 8 sessions of CBT-I via Zoom for the CBT-I group. * Subjects must be willing to come for pre/post assessment visits. * MoCA score of between 20-26. Exclusion Criteria: * Currently taking any of the following medications consistently: Benzodiazepines (ProSom, Restoril, Ativan and Xanax); Z Drugs (eszopiclone (Lunesta), zaleplon (Sonata |
| Ages | 60 Years |
| Sex | All |
| Lead sponsor | Rutgers, The State University of New Jersey |
| Locations | Newark, New Jersey, United States |
| Start date | 2025-06-02 |
| NCT ID | NCT06791356 |
| Official listing | https://clinicaltrials.gov/study/NCT06791356 |